Single-arm phase II study: Venetoclax added to Cladribine plus low-dose Cytarabine alternating with 5-Azacitidine in older patients with newly diagnosed acute myeloid leukemia.
30 Jun, 2022 | 10:14h | UTCPhase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia – Journal of Clinical Oncology (link to abstract – $ for full-text)